Matthew Faulkner

Manager, Global Business and Corporate Development

New York, United States


Licensing, M&A , and divestitures in the Health Care industry

Domain experience

Relevant Total Experience: 8 years

Seniority Level: Manager

Sector Experience: 

Pharmaceuticals, Biotechnology and Life Sciences


Skilled in: Corporate Development, Commercial Due Diligence, Financial Due Diligence, Term Sheet, M&A Negotiations, Licensing Agreements

Technical Skills: Microsoft Excel, PowerPoint, Bloomberg, Microsoft Office

Languages: English

Work Experience


Global Business and Corporate Development



- 1/7/2023

Viatris (Previously Mylan Pharmaceuticals) Manager, Global Business and Corporate Development  Responsible for sourcing, market analysis, technical due diligence, and execution of licensing and M&A opportunities for Biosimilars, Branded, and Generic drugs globally across early-stage and commercialized assets.  Create and maintain financial models (DCF, rNPV, Accretion/Dilution, IRR) and serve as the owner for all deal analytics and metrics.  Assisting in evaluating potential business development opportunities and developing business cases to accurately describe and disseminate the investment and potential returns of such programs, ultimately leading to approval via the Viatris executive management team.  Collaborate with cross-functional teams to identify and analyze new segments for business expansion. Work with senior business development colleagues to help assemble recommendations, present to Mylan leadership, and, pending approval, pursue external opportunities based on these plans. Deal Experience  Mylan, Pfizer (PFE) Upjohn merger: Part of the five-person Mylan deal team responsible for executing the Mylan, Pfizer Upjohn merger via Reverse Morris Trust transaction, creating Viatris with 2020 pro-forma revenues of $20 Billion and $22 Billion market cap. o Served as the ‘go-to’ internal resource for Mylan/Upjohn merger analytics, including market share analysis for both the combined NewCo and Mylan/Upjohn standalone global portfolios for use in merger negotiations. o Developed critical path product divestiture plan to satisfy regulatory approval requirements, coordinating with outside counsel and the FTC and EC resulting in the sale of over 20 molecules  Acquisition of Aspen Pharmaceuticals Thrombosis portfolio in the E.U o Worked with country managers across 27 E.U countries to build 5 year pro-forma projections; Built DCF and accretion/dilution analysis to value €260M portfolio with over 250 SKUs, worked with senior management in negotiations of the purchase price, supply terms, and deal structuring including $750M in upfront payments  Collaboration of Theravance Revefenacin for commercialization right in China o Worked with Mylan emerging markets team to build valuation for commercialization rights to China, used the initial model to structure upfront fees, regulatory milestones, as well as royalties on net sales and commercial milestones on cumulative aggregate net sales of all products.  Acquisition of Oyster Point Pharma and Famy Life Sciences  Divestment of Biosimilar division to Biocon Biologics  Licensing of Pimecrolimus for treatment of Blepharitis  Equity investment for Ph. II/III opportunity

Beacon Tree Capital

Senior Associate



- 1/7/2018

 Responsible for developing deal origination strategy, building operating models, valuation and managing transaction process including leading initial negotiations, issuing transactional documents with owner/operators, investment bankers, and other intermediaries in competitive bid process for lower middle-market companies.  Worked independently and led cross-functional teams to conduct operational and strategic due diligence for business risk and market risk, company assessment, competitor analysis, and post acquisition strategy.  Utilized LBO modeling in conjunction with relative and intrinsic valuation methodologies such as precedent transaction analysis, comparable company analysis ,and discounted cash flow modeling to determine enterprise value, and optimal capital structure.  Prepared investment memorandums and quarterly reports for management and limited partners.  Collected, analyzed and synthesized primary research gathered through various channels with industry experts and C-Level executives to enhance due diligence and secondary research.


Bentley University



- 01/06/2013